Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
暂无分享,去创建一个
I. Piña | G. Filippatos | T. Friede | L. Lund | M. Metra | J. Butler | P. Rossignol | F. Pinto | M. Weir | M. Kosiborod | P. van der Meer | A. Coats | F. Dorigotti | S. Anker | F. Pinto | U. Göhring | T. Siddiqi | B. Pitt | Carol Moreno Quinn | P. Szecsödy | Carol Moreno Quinn
[1] A. Sjölander,et al. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care , 2021, European journal of heart failure.
[2] L. Lund,et al. Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.
[3] G. Filippatos,et al. Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry , 2020, European journal of heart failure.
[4] L. Lund,et al. Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry , 2020, European journal of heart failure.
[5] S. Seliger. Hyperkalemia in patients with chronic renal failure. , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[6] P. Ponikowski,et al. Hyperkalemia and Treatment With RAAS-Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. , 2019, JACC. Heart failure.
[7] L. Lund,et al. Clinical and research implications of serum versus plasma potassium measurements , 2018, European journal of heart failure.
[8] L. Lund,et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry , 2018, European journal of heart failure.
[9] L. Lund,et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists , 2018, European journal of heart failure.
[10] G. Filippatos,et al. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease , 2018, ESC heart failure.
[11] P. Ponikowski,et al. Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT‐CHF , 2018, European journal of heart failure.
[12] L. Lund,et al. Hyperkalemia After Initiating Renin–Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project , 2017, Journal of the American Heart Association.
[13] P. Ponikowski,et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study , 2017, European heart journal.
[14] Volkmar Falk,et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2016, Revista espanola de cardiologia.
[15] G. Bakris,et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors , 2015, European journal of heart failure.
[16] N. Oestreicher,et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. , 2015, The American journal of managed care.
[17] P. Ponikowski,et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term Registry , 2013, European journal of heart failure.
[18] S. Pocock,et al. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities , 2011, European heart journal.
[19] Bertram Pitt,et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial , 2011, European heart journal.